Outlook Therapeutics Inc (OTLK) Reports Q1 Fiscal 2024 Results and Strategic Developments [Yahoo! Finance]
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
Earnings Per Share : Loss of $0.04 per basic and diluted share in Q1 FY2024, improved from a loss of $0.08 in the prior year. Cash Position : Cash and cash equivalents stood at $10.4 million as of December 31, 2023. Upcoming Financing : Entered into agreements for financing up to $172 million, subject to shareholder approval. Clinical Development : Received FDA agreement on NORSE EIGHT trial protocol, with the first subject enrolled in January 2024. Regulatory Pathway : Anticipates topline results and resubmission of the ONS-5010 BLA by the end of calendar year 2024. Market Potential : ONS-5010, if approved, would be the first FDA-approved ophthalmic formulation of bevacizumab. Warning! GuruFocus has detected 1 Warning Sign with OTLK. On February 14, 2024, Outlook Therapeutics Inc ( NASDAQ:OTLK ) released its 8-K filing , announcing its financial results for the first quarter of fiscal year 2024 and providing a corporate update. The company, a clinical-stage biopharmace
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics® to Present at the Retina World Congress 2024GlobeNewswire
- Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation ShowcaseGlobeNewswire
- Outlook Therapeutics® Announces Closing of Private Placement of $5.0 MillionGlobeNewswire
- Outlook Therapeutics: De-Risked Regulatory Tracks Are Lining Up For Possible ONS-5010 Approval [Seeking Alpha]Seeking Alpha
OTLK
Earnings
- 2/14/24 - Beat
OTLK
Sec Filings
- 5/6/24 - Form 424B3
- 5/1/24 - Form 8-K
- 4/26/24 - Form S-3
- OTLK's page on the SEC website